NASDAQ$BBIO
Bridgebio Pharma Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
BridgeBio reported financial results for Q3 2020 and provided a business update.
BridgeBio reported $710.7 million in cash, cash equivalents and marketable securities as of September 30, 2020. The company had an operating expense of $128.1 million for the quarter. The company also announced a merger agreement with Eidos Therapeutics and the FDA accepted the NDA for Fosdenopterin under Priority Review.
- BridgeBio and Eidos Therapeutics entered into a merger agreement.
- FDA accepted NDA for Fosdenopterin under Priority Review designation.
- Two new clinical trials were initiated since the last quarterly update and 15 ongoing clinical trials were progressed.
- Ended the quarter with $710.7 million in cash, cash equivalents, and marketable securities.
Headline financials
Revenue & EPS history
Bridgebio · Revenue · Quarterly
$8.13M
Revenue by segment
Bridgebio · $100K total across 1 segment · Q2 2023
- License and Services Revenue$100K—100.0%
Forward guidance
BridgeBio is nearing a significant inflection point as a company as it approaches the start of 2021.
Tailwinds
- Four key programs have critical data readouts within the next year and a half – in ATTR, achondroplasia, CAH and ADH1.
- Progressing 17 ongoing clinical trials.
- Preparing for commercialization, to bring the first investigational therapy to patients.
- Acoramidis: Topline results from Part A of the ATTRibute-CM trial are expected in late 2021 or early 2022 and from Part B in 2023.
- Low-dose infigratinib: Remain on track to report initial data from the ongoing Phase 2 dose ranging study by end of 2021.
Headwinds
- The longer-term impact of COVID-19 on operating expenses is currently unknown.
- Potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy
- The occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction with Eidos
- The risk that Eidos’ and/or BridgeBio’s stockholders may not approve the proposed transaction
- Uncertainty of the expected financial performance of each of Eidos and BridgeBio following completion of the proposed transaction
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+1.5%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.3%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+40.9%
Q2 2022
Best reaction
-21.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | -3.2% | -0.7% | |
| Q4 2025 | -2.8% | -4.1% | +2.0% | |
| Q3 2025 | -4.9% | -7.9% | +8.1% | |
| Q1 2025 | +5.3% | +4.9% | -6.0% | |
| Q4 2024 | +1.4% | -5.3% | -4.2% | |
| Q3 2024 | -5.1% | -9.2% | +5.9% | |
| Q2 2024 | +0.9% | -4.2% | +7.3% | |
| Q1 2024 | +3.0% | +2.8% | +3.6% | |
| Q4 2023 | -0.5% | +4.6% | -13.4% | |
| Q3 2023 | +8.2% | +10.3% | +16.1% | |
| Q2 2023 | -2.3% | +0.8% | -4.4% | |
| Q1 2023 | -5.0% | -4.4% | -1.0% | |
| Q4 2022 | -4.7% | -6.6% | +21.8% | |
| Q3 2022 | -1.1% | -7.0% | -4.8% | |
| Q2 2022 | +40.9% | +39.7% | +26.7% | |
| Q1 2022 | -21.9% | -29.5% | -15.9% | |
| Q4 2021 | +7.6% | +13.9% | +41.1% | |
| Q3 2021 | +6.8% | +2.0% | -22.8% | |
| Q2 2021 | +2.4% | -1.1% | -2.3% | |
| Q1 2021 | -9.3% | -7.2% | +9.5% | |
| Q4 2020 | +4.9% | -1.8% | -9.8% | |
| Q3 2020 | -1.6% | +0.3% | +30.4% | |
| Q2 2020 | +1.4% | +0.2% | +16.2% | |
| Q1 2020 | -6.8% | +6.1% | -12.7% | |
| Q4 2019 | +2.2% | -9.3% | -21.3% | |
| Q3 2019 | +22.1% | +26.2% | +49.0% | |
| Q2 2019 | +0.0% | +4.8% | -3.2% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro